Cargando…
Barth syndrome cardiomyopathy: targeting the mitochondria with elamipretide
Barth syndrome (BTHS) is a rare, X-linked recessive, infantile-onset debilitating disorder characterized by early-onset cardiomyopathy, skeletal muscle myopathy, growth delay, and neutropenia, with a worldwide incidence of 1/300,000–400,000 live births. The high mortality rate throughout infancy in...
Autor principal: | Sabbah, Hani N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895793/ https://www.ncbi.nlm.nih.gov/pubmed/33001359 http://dx.doi.org/10.1007/s10741-020-10031-3 |
Ejemplares similares
-
Elamipretide for Barth syndrome cardiomyopathy: gradual rebuilding of a failed power grid
por: Sabbah, Hani N.
Publicado: (2021) -
Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome
por: Hornby, Brittany, et al.
Publicado: (2022) -
Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data
por: Van den Eynde, Jef, et al.
Publicado: (2023) -
Barth Syndrome Cardiomyopathy: An Update
por: Pang, Jing, et al.
Publicado: (2022) -
Effects of elamipretide on skeletal muscle in dogs with experimentally induced heart failure
por: Sabbah, Hani N., et al.
Publicado: (2019)